331 related articles for article (PubMed ID: 35697170)
21. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma.
Mancinelli R; Cutone A; Rosa L; Lepanto MS; Onori P; Pannarale L; Franchitto A; Gaudio E; Valenti P
Eur J Histochem; 2020 Oct; 64(4):. PubMed ID: 33131269
[TBL] [Abstract][Full Text] [Related]
22. Pathological spectrum of bile duct lesions from chronic bile duct injury to invasive cholangiocarcinoma corresponding to bile duct imaging findings of occupational cholangiocarcinoma.
Kinoshita M; Kubo S; Nakanuma Y; Sato Y; Takemura S; Tanaka S; Hamano G; Ito T; Terajima H; Yamada T; Nakamori S; Arimoto A; Fujikawa M; Sugawara Y; Yamamoto T; Abue M; Nakagawa K; Unno M; Mizuguchi T; Takenaka K; Shirabe K; Shibata T
J Hepatobiliary Pancreat Sci; 2016 Feb; 23(2):92-101. PubMed ID: 26580863
[TBL] [Abstract][Full Text] [Related]
23. Preoperative subcategorization based on magnetic resonance imaging in intrahepatic cholangiocarcinoma.
Xiao Y; Zhou C; Ni X; Huang P; Wu F; Yang C; Zeng M
Cancer Imaging; 2023 Feb; 23(1):15. PubMed ID: 36782276
[TBL] [Abstract][Full Text] [Related]
24. Solid-Tubulocystic carcinoma: A new variant of intrahepatic cholangiocarcinoma.
González IA; Luo W; Zhang X
World J Hepatol; 2023 Jul; 15(7):897-903. PubMed ID: 37547028
[TBL] [Abstract][Full Text] [Related]
25. Development of intraductal papillary neoplasm of the bile duct in patients with occupational cholangiocarcinoma.
Kubo S; Tanaka S; Kinoshita M; Shinkawa H; Ishizawa T; Sato Y
Virchows Arch; 2023 Apr; 482(4):745-753. PubMed ID: 36715769
[TBL] [Abstract][Full Text] [Related]
26. Role of immunophenotypic characterisation in prognostic subtyping of intrahepatic cholangiocarcinoma.
Li Z; Huang N; Du Q; Huang W; Wang B; Wang B; Shen G; Zhang H; Shi S; Wang L
Pathology; 2023 Dec; 55(7):979-988. PubMed ID: 37858435
[TBL] [Abstract][Full Text] [Related]
27. Intraductal papillary neoplasms of the bile duct consist of two distinct types specifically associated with clinicopathological features and molecular phenotypes.
Aoki Y; Mizuma M; Hata T; Aoki T; Omori Y; Ono Y; Mizukami Y; Unno M; Furukawa T
J Pathol; 2020 May; 251(1):38-48. PubMed ID: 32100878
[TBL] [Abstract][Full Text] [Related]
28. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.
Kendre G; Murugesan K; Brummer T; Segatto O; Saborowski A; Vogel A
J Hepatol; 2023 Mar; 78(3):614-626. PubMed ID: 36528236
[TBL] [Abstract][Full Text] [Related]
29. Challenges in Diagnosing and Reporting Cholangiocarcinoma.
El Jabbour T; Molnar A; Lagana SM
Surg Pathol Clin; 2023 Sep; 16(3):599-608. PubMed ID: 37536891
[TBL] [Abstract][Full Text] [Related]
30. New epidemiologic trends in cholangiocarcinoma.
Pascale A; Rosmorduc O; Duclos-Vallée JC
Clin Res Hepatol Gastroenterol; 2023 Nov; 47(9):102223. PubMed ID: 37797807
[TBL] [Abstract][Full Text] [Related]
31. Enteroblastic cholangiocarcinoma: An uncommon, underrecognized subtype of bile duct cancer.
Chun J; Moore M; Kelly P; Kanzawa M; Itoh T; Hong SM; Zen Y
Hum Pathol; 2024 Feb; 144():46-52. PubMed ID: 38301963
[TBL] [Abstract][Full Text] [Related]
32. Solid-Tubulocystic Variant of Intrahepatic Cholangiocarcinoma: Report of a Pediatric Case With Molecular Characterization.
González IA; Linn RL; Wilkins BJ
Pediatr Dev Pathol; 2022; 25(6):661-667. PubMed ID: 36031872
[TBL] [Abstract][Full Text] [Related]
33. FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A; Segatto O; Stenzinger A; Saborowski A
Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
[TBL] [Abstract][Full Text] [Related]
34. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
[TBL] [Abstract][Full Text] [Related]
35. Pathology of Cholangiocarcinomas.
Guedj N
Curr Oncol; 2022 Dec; 30(1):370-380. PubMed ID: 36661679
[TBL] [Abstract][Full Text] [Related]
36. Radiologic spectrum of cholangiocarcinoma: emphasis on unusual manifestations and differential diagnoses.
Lee WJ; Lim HK; Jang KM; Kim SH; Lee SJ; Lim JH; Choo IW
Radiographics; 2001 Oct; 21 Spec No():S97-S116. PubMed ID: 11598251
[TBL] [Abstract][Full Text] [Related]
37. A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.
Rhee H; Kim MJ; Park YN; An C
Eur Radiol; 2019 Jun; 29(6):3111-3121. PubMed ID: 30560357
[TBL] [Abstract][Full Text] [Related]
38. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Martin-Serrano MA; Kepecs B; Torres-Martin M; Bramel ER; Haber PK; Merritt E; Rialdi A; Param NJ; Maeda M; Lindblad KE; Carter JK; Barcena-Varela M; Mazzaferro V; Schwartz M; Affo S; Schwabe RF; Villanueva A; Guccione E; Friedman SL; Lujambio A; Tocheva A; Llovet JM; Thung SN; Tsankov AM; Sia D
Gut; 2023 Apr; 72(4):736-748. PubMed ID: 35584893
[TBL] [Abstract][Full Text] [Related]
39. Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch-repair deficiency.
Makino K; Ishii T; Takeda H; Saito Y; Fujiwara Y; Fujimoto M; Ito T; Wakama S; Kumagai K; Munekage F; Horie H; Tomofuji K; Oshima Y; Uebayashi EY; Kawai T; Ogiso S; Fukumitsu K; Takai A; Seno H; Hatano E
J Pathol; 2024 May; 263(1):32-46. PubMed ID: 38362598
[TBL] [Abstract][Full Text] [Related]
40. A statement by the Japan-Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage.
Nakanuma Y; Jang KT; Fukushima N; Furukawa T; Hong SM; Kim H; Lee KB; Zen Y; Jang JY; Kubota K
J Hepatobiliary Pancreat Sci; 2018 Mar; 25(3):181-187. PubMed ID: 29272078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
